Torres Denice — SEC insider filings
SEC reporting owner CIK 1820278. 32 insider filings on record with FilingPulse; latest filed 2026-11-04.
Transaction summary — filings shown
Covers all 32 filings on record, filed 2020-08-11 to 2026-11-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 5,000 shares, $99,325 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 56.
- Largest priced transaction: purchase of 5,000 shares @ $19.86 ($99,325) in Seaport Therapeutics, Inc., filed 2026-11-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | Director | 2 | 1 leg · 5,000 sh · $99,325 | — | 3 |
| GLAUKOS Corp (GKOS) | Director | 12 | — | — | 17 |
| 2seventy bio, Inc. (TSVT) | Director | 5 | — | — | 13 |
| Karuna Therapeutics, Inc. (KRTX) | Director | 5 | — | — | 10 |
| bluebird bio, Inc. (BLUE) | Director | 3 | — | — | 8 |
| Surface Oncology, Inc. (SURF) | Director | 3 | — | — | 3 |
| Celldex Therapeutics, Inc. (CLDX) | Director | 2 | — | — | 2 |
Insider filings — Torres Denice
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-04 | 4 | Seaport Therapeutics, Inc. (SPTX) | Purchase (P): 5,000 @ $19.86 | EDGAR |
| 2026-06-29 | 4 | Celldex Therapeutics, Inc. (CLDX) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4/A | GLAUKOS Corp (GKOS) | Grant/award (A): 2,987 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 1,878 @ $0 · Grant/award (A): 2,987 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Seaport Therapeutics, Inc. (SPTX) | Conversion (C): 13,406 · Grant/award (A): 12,258 (derivative) @ $0 · Conversion (C): 42,105 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 623 @ $0 | EDGAR |
| 2025-06-09 | 4 | Celldex Therapeutics, Inc. (CLDX) | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 461 @ $0 · Grant/award (A): 2,108 @ $0 · Grant/award (A): 3,149 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | 2seventy bio, Inc. (TSVT) | Disposition to issuer (D): 12,050 · Code (U): 19,510 · Disposition to issuer (D): 24,100 (derivative) | EDGAR |
| 2024-06-12 | 4 | 2seventy bio, Inc. (TSVT) | Grant/award (A): 12,050 @ $0 · Grant/award (A): 24,100 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 1,716 @ $0 · Grant/award (A): 1,246 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Karuna Therapeutics, Inc. (KRTX) | Disposition to issuer (D): 990 @ $330 · Disposition to issuer (D): 25,000 (derivative) @ $225.74 · Disposition to issuer (D): 8,500 (derivative) @ $201.99 · Disposition to issuer (D): 5,000 (derivative) @ $227.04 · Disposition to issuer (D): 1,904 (derivative) @ $92.30 | EDGAR |
| 2024-01-04 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 895 @ $0 | EDGAR |
| 2023-06-22 | 4 | Karuna Therapeutics, Inc. (KRTX) | Grant/award (A): 990 @ $0 · Grant/award (A): 1,904 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | 2seventy bio, Inc. (TSVT) | Grant/award (A): 8,400 @ $0 · Grant/award (A): 16,900 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 3,230 @ $0 | EDGAR |
| 2023-01-04 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 1,572 @ $0 | EDGAR |
| 2022-06-16 | 4 | Karuna Therapeutics, Inc. (KRTX) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Surface Oncology, Inc. (SURF) | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | 2seventy bio, Inc. (TSVT) | Grant/award (A): 8,200 @ $0 · Grant/award (A): 16,900 (derivative) @ $0 | EDGAR |
| 2022-06-06 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 4,364 @ $0 | EDGAR |
| 2022-01-05 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 1,455 @ $0 | EDGAR |
| 2022-01-05 | 4 | Surface Oncology, Inc. (SURF) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2021-11-17 | 4 | bluebird bio, Inc. (BLUE) | Other (J): 1,476 @ $0 · Other (J): 0 @ $0 · Disposition to issuer (D): 4,500 (derivative) @ $0 · Disposition to issuer (D): 5,000 (derivative) @ $0 | EDGAR |
| 2021-11-16 | 4 | 2seventy bio, Inc. (TSVT) | Grant/award (A): 492 @ $0 · Grant/award (A): 2,002 @ $0 · Grant/award (A): 1,476 (derivative) @ $0 · Grant/award (A): 3,219 (derivative) @ $0 | EDGAR |
| 2021-08-03 | 4 | Surface Oncology, Inc. (SURF) | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2021-06-23 | 4 | Karuna Therapeutics, Inc. (KRTX) | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | bluebird bio, Inc. (BLUE) | Grant/award (A): 3,109 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2021-06-07 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 2,382 @ $0 | EDGAR |
| 2021-03-03 | 4 | GLAUKOS Corp (GKOS) | Grant/award (A): 3,079 @ $0 · Grant/award (A): 449 @ $0 | EDGAR |
| 2020-12-22 | 4 | Karuna Therapeutics, Inc. (KRTX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2020-08-11 | 4 | bluebird bio, Inc. (BLUE) | Grant/award (A): 2,250 @ $0 · Grant/award (A): 4,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1820278 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs